Hongda Ding

Hongda Ding

Auto-generated profile, based on publicly available information

Hongda Ding

Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2020 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
HDHongda Ding
Hongda Ding
JLJunpeng Liu
Junpeng Liu
CWCaibin Wang
Caibin Wang
YSYang Su
Yang Su
Background: Dysregulation of fatty acid (FA) metabolism is involved in hepatocellular carcinoma (HCC) development. Non-POU domain-containing octamer binding protein (NONO), known as the component of nuclear paraspeckles, has recently been found to promote HCC progression. In this study, we investigated the functions of NONO in regulating de novo FA synthesis and its underling mechanism during HCC development. Methods: The roles of NONO in HCC development by applying gene function loss analysis in HCC cells were detected by quantitative real-time polymerase chain reaction, cell proliferation, and cell invasion assays. The underlying mechanism of NONO in HCC development was examined by western blotting, subcellular fractionation, RNA-binding protein immunoprecipitation-sequencing, chromatin immunoprecipitation, co-immunoprecipitation and mass spectrometry. The effect of NONO on tumorigenesis in vivo was performed with a subcutaneous xenograft mouse model of HCC. Results: NONO promotes HCC progression by interacting with and increasing ATP-citrate lyase (ACLY) mRNA to enhance FA biosynthesis. Furthermore, NONO promotes ACLY expression through enhancing nuclear ACLY mRNA stability in Diethylnitrosamine-stimulated HCC cells, not related to nuclear paraspeckles. Moreover, we find that NONO/SFPQ (Splicing factor proline and glutamine rich) heterodimer is essential for NONO interacting with ACLY mRNA in DEN stimulated HCC cells. In addition, NONO, Insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) and ACLY expressions contribute HCC development in mice and are related to poor survival. Conclusion: NONO promotes HCC progression by enhancing FA biosynthesis through interacting with ACLY mRNA and provide a novel potential target for HCC therapy.

17 October 2025 in Hepatology
Verified
Journal Article
Closed access
SWShuai Wang
Shuai Wang
PWPeihan Wu
Peihan Wu
NXNan Xu
Nan Xu
ZXZhaoFeng Xiao
ZhaoFeng Xiao
YLYanPeng Liu
YanPeng Liu
HDHongDa Ding
HongDa Ding
Background and Aims: Immune-checkpoint inhibitors target the membrane protein; however, the role of membrane proteins in antitumor immunity remains poorly elucidated. In this study, we aimed to explore the role of membrane proteins and unearth potential membrane proteins that can be targeted. Approach and Results: We initially screened prognosis-related membrane proteins based on The Cancer Genome Atlas Program and International Cancer Genome Consortium databases. Whole-gene, T-cell–specific or CD8T-cell–specific integral membrane protein 2A (ITM2A) knockout mice were constructed and used for orthotopic transplantation or as plasmid-derived spontaneous hepatocellular carcinoma (HCC) models to explore the role of ITM2A in the tumor microenvironment (TME). Through single-cell RNA sequencing (scRNA-seq), TimiGP analysis, molecular dynamics simulations, and biochemical experiments, the molecular mechanisms underlying the MSR1–ITM2A–TCR signaling regulatory axis were explored. Finally, bioengineering technologies were used to design and construct a new CD4T-targeted antibody–drug conjugate (ADC). High ITM2A expression in HCC indicated a superior prognosis, which was associated with richer immune cell infiltration in the TME. The results of the scRNA-seq of the HCC model in genetically knocked-out mice suggest that ITM2A influences the TCR signaling of tumor-infiltrating lymphocytes in the TME. This inference was confirmed in conditional ITM2A knockout mice. MSR1 + macrophages induced CD4T exhaustion by disrupting the ITM2A–ZAP70 axis during TCR activation. ADC (ZEA-αCD4) treatment effectively inhibited tumor growth, independent of the classical αPDL1 immunotherapy. Conclusions: MSR1 + macrophages promote tumor-infiltrating ITM2A + CD4T exhaustion differentiation by regulating the ITM2A–ZAP70 axis. ZEA-αCD4 specifically targeted the MSR1–ITM2A interaction to activate antitumor immunity and improve the efficacy of αPDL1 immunotherapy.

14 August 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ZXZhaofeng Xiao
Zhaofeng Xiao
LMLijun Meng
Lijun Meng
SXShengjun Xu
Shengjun Xu
NXNan Xu
Nan Xu
YLYe Li
Ye Li
XTXiaodong Tan
Xiaodong Tan
Background: Tumor-derived lactate has long been regarded as a metabolic waste product. However, accumulating evidence indicates that lactate also functions as a signaling molecule that actively remodels the tumor immune microenvironment. How lactate-driven post-translational modifications in immune cells contribute to immune evasion in hepatocellular carcinoma (HCC) remains incompletely understood. This study aimed to identify the immune cell population responsible for lactylation-driven immunosuppression in HCC and to elucidate the molecular mechanism by which lactylation rewires macrophage metabolism to impair CD8 + T cell-mediated antitumor immunity. Methods: Selective in vivo immune cell depletion models were employed to define the key immune mediators of lactate-induced immunosuppression. Proteomic screening, site-directed mutagenesis, and lipidomic profiling were used to characterize lactylation targets and lipid metabolic alterations. Functional assays, including signaling pathway analyses, cytokine measurements, and tumor immune profiling, were performed in both in vitro systems and mouse HCC models. Results: Macrophages were identified as the principal immune cell type mediating lactylation-dependent immunosuppression in HCC. Alanyl-tRNA synthetase 1 (AARS1) functioned as a non-canonical lactyltransferase, catalyzing lactylation of carnitine palmitoyltransferase 1A at lysine 675. This modification impaired long-chain fatty acid transport into mitochondria, leading to cytosolic accumulation of oleic acid (OA). OA directly disrupted cGAS binding to cytosolic DNA, thereby suppressing STING activation and type I interferon (IFN-I) production. Attenuated IFN-I signaling resulted in reduced major histocompatibility complex-I expression on tumor cells and impaired CD8 + T cell-mediated recognition and cytotoxicity. Conclusion: These findings uncover a lactate-lipid metabolism axis that links tumor-derived lactate to innate immune suppression in HCC. Targeting AARS1-mediated lactylation represents a potential therapeutic strategy to restore macrophage immunostimulatory function and enhance antitumor immunity.

20 July 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
NXNan Xu
Nan Xu
YSYisu Song
Yisu Song
ZXZhaofeng Xiao
Zhaofeng Xiao
YCYiyuan Chen
Yiyuan Chen
LMLijun Meng
Lijun Meng
JWJian Wu
Jian Wu
Hepatocellular carcinoma (HCC) remains a major cause of cancer-related death worldwide, with limited efficacy of current immunotherapies due to an immunosuppressive tumor microenvironment and dysfunctional CD8⁺ tumor-infiltrating lymphocytes (TILs). Among these, PD-1⁺CD25⁺ CD8⁺ T cells represent a tumor-reactive subset linked to IL-2 responsiveness and favorable responses to PD-1 blockade. In this study, we integrated single-cell and spatial transcriptomics with clinical immunotherapy cohort analyses to characterize the phenotype and function of PD-1⁺CD25⁺ CD8⁺ TILs in human HCC. To therapeutically exploit this subset, we engineered IL-2(N88D)/CD25 fusion proteins with trimeric receptor bias, selectively promoting the expansion of PD-1⁺CD25⁺ CD8⁺ T cells. These constructs were tested in multiple murine HCC models, including orthotopic and hydrodynamic tail vein injection systems. PD-1⁺CD25⁺ CD8⁺ TILs were enriched in HCC tumors, particularly in immunotherapy responders, and exhibited enhanced tumor reactivity and neoantigen specificity. Treatment with IL-2/CD25 led to increased CD8⁺ T cell infiltration and delayed tumor progression with minimal toxicity, while the IL-2(N88D)/CD25 variant further boosted infiltration, activation, and survival outcomes. These findings highlight the therapeutic potential of selectively activating antigen-specific CD8⁺ T cells via IL-2(N88D)/CD25 fusion proteins, offering a promising strategy for improving HCC immunotherapy.

14 October 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
RZRuoyao Zou
Ruoyao Zou
LYLiangqing Yao
Liangqing Yao
YWYongfeng Wu
Yongfeng Wu
FLFei Lv
Fei Lv
HHHaoqi Han
Haoqi Han
JTJinyi Tong
Jinyi Tong
Ovarian cancer is a leading cause of gynecological cancer-related mortality, with its immunosuppressive tumor microenvironment (TME) limiting the effectiveness of immune checkpoint inhibitor therapy. Alanyl-tRNA synthetase 1 (AARS1) expression in ovarian cancer has been linked to poor prognosis; however, its immunological role remains unclear. In this study, we generated an Aars1-knockdown ID8 syngeneic mouse model to evaluate the role of AARS1 in vivo. Immune infiltration was assessed using flow cytometry and immunohistochemistry. Multi-omics profiling, including single-cell RNA sequencing (scRNA-seq), Ribo-seq, and ATAC-seq, was used to dissect underlying mechanisms. A small-molecule library screen, molecular dynamics simulations, and functional assays were used to identify compounds targeting AARS1. AARS1 depletion suppressed tumor progression, remodeled the TME, decreased myeloid-derived suppressor cells and tumor-associated macrophages, and increased cytotoxic T-lymphocyte (CTL) infiltration. Mechanistically, AARS1 interacted with NAT10 to regulate ribosomal loading of Irf7 mRNA, thereby attenuating type I interferon (IFN-I) signaling. Screening identified deleobuvir as a potent AARS1-binding molecule that disrupted the AARS1–NAT10–mRNA complex, restored IFN-I signaling, and enhanced antitumor immunity. Targeting AARS1 in ovarian cancer promotes CTL infiltration and sensitizes tumors to antitumor immunity.